Literature DB >> 25319963

Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice.

Zacharias G Laoutidis1, Kanellos T Kioulos.   

Abstract

RATIONALE: The primary antipsychotic-induced creatine kinase elevation (i.e., not due to neuroleptic malignant syndrome, extrapyramidal symptoms, etc.) is a poorly studied condition.
OBJECTIVES: The aims of the present study were to provide an overview of published cases with antipsychotic-induced creatine kinase elevation and give recommendations for the clinical practice.
METHODS: PubMed and EMBASE were searched for eligible trials, case series, and case reports. We set a threshold at ten times the upper normal limit of the creatine kinase value in order to define an elevation as significant.
RESULTS: The prevalence of significant creatine kinase elevation ranged between 2 and 7%. We found a total of 42 eligible cases. Men were overrepresented in our sample (81%). Patients with myoglobinuria were more likely to be symptomatic (Fisher's exact test, p = 0.006), whereas neither myoglobinuria (Mann-Whitney test, p > 0.10) nor symptoms (Mann-Whitney test, p = 0.64) were related to the magnitude of the creatine kinase (CK) elevation. In the majority of the cases, the antipsychotic medication was discontinued (86%). Forced diuresis was given in 36% of the patients. Eighty-three percent of the patients had no further complications. Only one case was found with a de novo acute renal failure.
CONCLUSIONS: The discontinuation of the antipsychotic medication was a sufficient measure for the CK elevation to subside in the majority of the cases. Cases with myoglobinuria should eventually be treated more aggressively. Further recommendations for the clinical practice are presented.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25319963     DOI: 10.1007/s00213-014-3764-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  60 in total

1.  Severe elevations in serum creatine kinase associated with clozapine.

Authors:  J I Kirson; H L McQuistion; D W Pierce
Journal:  J Clin Psychopharmacol       Date:  1995-08       Impact factor: 3.153

2.  Acute rhabdomyolysis during treatment with amisulpride and metformin.

Authors:  Francesco Ursini; Elena Succurro; Alessandro Grembiale; Franco Arturi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-18       Impact factor: 2.953

3.  Rhabdomyolysis associated with haloperidol without evidence of NMS.

Authors:  M A Marinella
Journal:  Ann Pharmacother       Date:  1997 Jul-Aug       Impact factor: 3.154

4.  Myotoxicity and neurotoxicity during clozapine treatment.

Authors:  I Reznik; L Volchek; R Mester; M Kotler; I Sarova-Pinhas; B Spivak; A Weizman
Journal:  Clin Neuropharmacol       Date:  2000 Sep-Oct       Impact factor: 1.592

5.  Creatine kinase elevations with clozapine.

Authors:  M S Keshavan; J Stecker; R K Kambhampati
Journal:  Br J Psychiatry       Date:  1994-01       Impact factor: 9.319

6.  Rhabdomyolysis with erratic serum creatinin phosphokinase levels: intramuscular injection of haloperidol decanoate.

Authors:  Premnath Reddy Karre; Jeetinder Gujral; Ernesto Rodriguez
Journal:  BMJ Case Rep       Date:  2009-08-17

7.  Marked elevation of serum creatine kinase associated with olanzapine therapy.

Authors:  E L Marcus; A Vass; J Zislin
Journal:  Ann Pharmacother       Date:  1999-06       Impact factor: 3.154

Review 8.  Risperidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Sandra Schwarz; Franziska Schmid; Heike Hunger; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

Review 9.  The syndrome of rhabdomyolysis: complications and treatment.

Authors:  Yiannis S Chatzizisis; Gesthimani Misirli; Apostolos I Hatzitolios; George D Giannoglou
Journal:  Eur J Intern Med       Date:  2008-04-28       Impact factor: 4.487

10.  Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.

Authors:  Paul D Martin; Mike J Warwick; Aaron L Dane; Steve J Hill; Petrina B Giles; Paul J Phillips; Eva Lenz
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  5 in total

Review 1.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

2.  Comparison of the effects of minimally invasive percutaneous pedicle screws osteosynthesis and open surgery on repairing the pain, inflammation and recovery of thoracolumbar vertebra fracture.

Authors:  Yahui Gong; Guangmin Fu; Bo Li; Yinan Li; Xiaoning Yang
Journal:  Exp Ther Med       Date:  2017-08-25       Impact factor: 2.447

3.  A Case of Psychosis and Renal Failure Associated with Excessive Energy Drink Consumption.

Authors:  D Kelsey; A J Berry; R A Swain; S Lorenz
Journal:  Case Rep Psychiatry       Date:  2019-07-24

4.  Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.

Authors:  Laurent Béchard; Olivier Corbeil; Marc-André Thivierge; Ibrahim Assaad; Camille Boulanger; Marie-Pierre Mailhot; Alexis Turgeon-Fournier; Marc-André Roy; Marie-France Demers
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

5.  Exceptionally high creatine kinase levels in risperidone-induced neuroleptic malignant syndrome: A case report.

Authors:  Siddiqa Ozaal; Gaya Katulanda
Journal:  SAGE Open Med Case Rep       Date:  2022-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.